Senti Biosciences Holdings (SNTI) Total Current Liabilities (2021 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly Total Current Liabilities of $14.0 million for Q4 2025, up 6.3% year-over-year from $13.1 million in Q4 2024, and up 16.19% quarter-over-quarter from $12.0 million in Q3 2025.
Senti Biosciences Holdings (SNTI) Total Current Liabilities (2021 - 2025) Analysis & Trends
Senti Biosciences Holdings' Total Current Liabilities history runs 5 years deep, the most recent figure standing at $14.0 million for Q4 2025.
- In Q4 2025, Total Current Liabilities rose 6.3% year-over-year to $14.0 million; the TTM figure through Dec 2025 stood at $14.0 million (up 6.3% YoY), while the FY2025 annual figure was $14.0 million, up 6.3% from the prior year.
- Total Current Liabilities for Q4 2025 stood at $14.0 million, up from $12.0 million in the prior quarter.
- The five-year high for Total Current Liabilities was $18.1 million in Q4 2022, with the low at $61025.0 in Q2 2021.
- The 5-year median for Total Current Liabilities is $10.7 million (2025), against an average of $10.7 million.
- The sharpest annual moves came in 2022 and 2023: Total Current Liabilities soared 29065.1% in 2022, then sank 41.42% in 2023.
- Senti Biosciences Holdings' Total Current Liabilities stood at $14.5 million in 2021, then grew by 24.14% to $18.1 million in 2022, then declined by 29.81% to $12.7 million in 2023, then gained by 3.74% to $13.1 million in 2024, then advanced by 6.3% to $14.0 million in 2025.
- Business Quant data shows SNTI's Total Current Liabilities at $14.0 million in Q4 2025, $12.0 million in Q3 2025, and $10.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.99 Bn | 132.14 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.80 Bn | 78.80 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.38 Bn | 60.19 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 60.70 Bn | 55.56 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.21 Bn | 26.37 Bn | - | 630.93 Mn |
| 10 | Senti Biosciences Holdings | 12.92 Mn | 12.92 Mn | - | 15.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 13.97 Mn |
| Sep 30, 2025 | 12.03 Mn |
| Jun 30, 2025 | 9.99 Mn |
| Mar 31, 2025 | 10.73 Mn |
| Dec 31, 2024 | 13.15 Mn |
| Sep 30, 2024 | 9.06 Mn |
| Jun 30, 2024 | 9.07 Mn |
| Mar 31, 2024 | 9.61 Mn |
| Dec 31, 2023 | 12.67 Mn |
| Sep 30, 2023 | 10.11 Mn |
| Jun 30, 2023 | 10.43 Mn |
| Mar 31, 2023 | 12.87 Mn |
| Dec 31, 2022 | 18.05 Mn |
| Sep 30, 2022 | 15.84 Mn |
| Jun 30, 2022 | 17.80 Mn |
| Mar 31, 2022 | 4.05 Mn |
| Dec 31, 2021 | 14.54 Mn |
| Sep 30, 2021 | 128,846.00 |
| Jun 30, 2021 | 61,025.00 |